secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001437749-24-034338
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva: 108 patients complete 1-year brilaroxazine OLE; topline data expected Dec 2024
--------------------------------------------------------------------------------

- 108 patients completed 12-month treatment; over 250 completed 6 months in the OLE study.
- Long-term safety data from 100 patients with 12 months treatment now available for planned NDA submission.
- Brilaroxazine continues to be generally well tolerated in acute and stable schizophrenia patients.
- Topline 12-month long-term safety and efficacy data expected in December 2024.
- OLE study (RECOVER) completion anticipated in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/0001437749-24-034338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924034338/rvph20241111_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer